
    
      Study Design: Open-label, single-dose, two-period, three-treatment, fixed-sequence,
      comparative bioavailability study Study Population: Non-smoking, male and female subjects,
      from 18 to 55 years of age with known history of hay fever, seasonal allergies, or rhinitis
      during the last year.
    
  